Back to Journals » OncoTargets and Therapy » Volume 5

β-blockers: a novel class of antitumor agents

Authors Ji Y , Chen S, Xiao, Shan, Kai

Received 21 September 2012

Accepted for publication 25 October 2012

Published 26 November 2012 Volume 2012:5 Pages 391—401

DOI https://doi.org/10.2147/OTT.S38403

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5



Yi Ji,1,* Siyuan Chen,2,* Xianmin Xiao,1 Shan Zheng,1 Kai Li,1

1Division of Oncology, Department of Pediatric Surgery, 2Research Institute of Pediatrics, Children's Hospital of Fudan University, Shanghai, China

*These authors contributed equally to this work

Abstract: β-adrenergic signaling modulates key signaling pathways that are important for tumor-promoting processes, and numerous mechanisms of action have been elucidated. Preclinical studies have demonstrated that β-adrenergic antagonists, or β-blockers, can block multiple fundamental biologic processes underlying the progression and metastasis of tumors, including the inhibition of cell proliferation, migration, invasion, resistance to programmed cell death, and tumor angiogenesis and metastasis. Human pharmacoepidemiologic studies suggest that β-blockers have a role in inhibiting cancer progression and metastasis in combination with standard therapies. Furthermore, a number of prospective studies have demonstrated that β-blockers are effective at halting infantile hemangioma growth. These findings shed light on the novel perspective of using β-blockers as a class of potential antitumor agents in clinical oncology.

Keywords: β-adrenergic signaling, cancer, β-blockers, progression, metastasis, angiogenesis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.